<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHYLDOPA AND HYDROCHLOROTHIAZIDE- methyldopa and hydrochlorothiazide tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="b_warning"></a><a name="section-1"></a><p></p>
<h1>WARNING</h1>
<p class="First">This fixed combination drug is not indicated for initial therapy of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is not static, but must be re-evaluated as conditions in each patient warrant.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_1b7422f0-5812-4ca1-8c8d-7997b1eea426"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">This fixed combination product combines two antihypertensives: methyldopa and hydrochlorothiazide.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_670b4da4-a9f9-4bb2-baa1-f62c9e9cadc2"></a><a name="section-1.1"></a><p></p>
<h2>Methyldopa</h2>
<p class="First">Methyldopa is an antihypertensive and is the <span class="Italics">L</span>-isomer of alpha-methyldopa. It is levo-3-(3,4-Dihydroxy-phenyl)-2-methylalanine sesquihydrate. Its molecular formula is C<span class="Sub">10</span>H<span class="Sub">13</span>NO<span class="Sub">4</span>•1 ½ H<span class="Sub">2</span>O with a molecular weight of 238.24, and its structural formula is:</p>
<div class="Figure">
<a name="id468"></a><img alt="Methyldopa Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5bf74178-66b8-44d4-a87d-1fd760b94ad3&amp;name=20299cba-fa9a-40ff-9737-06e052920321-01.jpg">
</div>
<p>Methyldopa is a white to yellowish white, odorless fine powder and is sparingly soluble in water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab2b51d9-73d9-424c-acd9-2b27258c8ee8"></a><a name="section-1.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-Chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its molecular formula is C<span class="Sub">7</span>H<span class="Sub">8</span>CIN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2 </span>and its structural formula is:</p>
<div class="Figure">
<a name="id484"></a><img alt="Hydrochlorothiazide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5bf74178-66b8-44d4-a87d-1fd760b94ad3&amp;name=20299cba-fa9a-40ff-9737-06e052920321-02.jpg">
</div>
<p>Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.75 which is slightly soluble in water, but freely soluble in sodium hydroxide solution.</p>
<p>Each tablet for oral administration contains:</p>
<p>250 mg methyldopa and 15 mg<br>hydrochlorothiazide,<br>or<br>250 mg methyldopa and 25 mg<br>hydrochlorothiazide.</p>
<p>Potency for methyldopa is calculated on anhydrous basis. Each tablet also contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, D&amp;C Yellow #10 Aluminum Lake, FD&amp;C Blue #1 Aluminum Lake, FD&amp;C Yellow #6 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide and triacetin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_438576e1-b371-4778-b5e4-99cf626620d4"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ccab2b8-8831-422e-9a13-e029922f30ad"></a><a name="section-2.1"></a><p></p>
<h2>Methyldopa</h2>
<p class="First">Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity. Methyldopa has been shown to cause a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine, and epinephrine.</p>
<p>Only methyldopa, the <span class="Italics">L</span>-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man, the antihypertensive activity appears to be due solely to the <span class="Italics">L</span>-isomer. About twice the dose of the racemate (<span class="Italics">DL</span>-alpha-methyldopa) is required for equal antihypertensive effect.</p>
<p>Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac output</span> usually is maintained without cardiac acceleration. In some patients the heart rate is slowed.</p>
<p>Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy.</p>
<p>Methyldopa reduces both supine and standing blood pressure. It usually produces highly effective lowering of the supine pressure with infrequent symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. Exercise <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and diurnal blood pressure variations rarely occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_adecbb7d-8aa2-4fe6-8c6c-0719650e0c42"></a><a name="section-2.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide does not usually affect normal blood pressure.</p>
<p>Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy.</p>
<p>Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>After oral use <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_1e6fb23d-2f22-419e-9f1f-fc281b5af4d6"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bf688d6-dca7-451b-b6c8-e2be5ac103f6"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="Bold">Methyldopa</span></h3>
<p class="First">The maximum decrease in blood pressure occurs four to six hours after oral dosage. Once an effective dosage level is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. After withdrawal, blood pressure usually returns to pretreatment levels within 24 to 48 hours.</p>
<p>Methyldopa is extensively metabolized. The known urinary metabolites are: α- methyldopa mono-O-sulfate; 3-O-methyl-α-methyldopa; 3,4-dihydroxyphenyl acetone; α-methyldopamine; 3-O-methyl-α–methyldopamine and their conjugates.</p>
<p>Approximately 70 percent of the drug which is absorbed is excreted in the urine as methyldopa and its mono-O-sulfate conjugate. The renal clearance is about 130 mL/min in normal subjects and is diminished in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. The plasma half-life of methyldopa is 105 minutes. After oral doses, excretion is essentially complete in 36 hours.</p>
<p>Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b26222fb-21a9-4d92-804f-f96b8f22d913"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_60272dfc-d0a6-4592-86d2-11d9c708df6d"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> - (see <a href="#b_warning">box WARNING</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Methyldopa and hydrochlorothiazide tablets are contraindicated in patients:</p>
<dl>
<dt>•</dt>
<dd>with active <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, such as acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and active cirrhosis.</dd>
<dt>•</dt>
<dd>with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> previously associated with methyldopa therapy (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</dd>
<dt>•</dt>
<dd>with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>.</dd>
<dt>•</dt>
<dd>with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to methyldopa, or to hydrochlorothiazide or other sulfonamide-derived drugs.</dd>
<dt>•</dt>
<dd>on therapy with monoamine oxidase (MAO) inhibitors.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_38c130ae-d642-418f-92a8-a4ca5810775e"></a><a name="section-5.1"></a><p></p>
<h2>Methyldopa</h2>
<p class="First"><span class="Bold">It is important to recognize that a positive Coombs test, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> may occur with methyldopa therapy. The rare occurrences of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> could lead to potentially fatal complications unless properly recognized and managed. Read this section carefully to understand these reactions.</span></p>
<p>With prolonged methyldopa therapy, 10 to 20 percent of patients develop a positive direct Coombs test which usually occurs between 6 and 12 months of methyldopa therapy. Lowest incidence is at a daily dosage of 1 g or less. This on rare occasions may be associated with <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, which could lead to potentially fatal complications. One cannot predict which patients with a positive direct Coombs test may develop <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
<p>Prior existence or development of a positive direct Coombs test is not in itself a contraindication to use of methyldopa. If a positive Coombs test develops during methyldopa therapy, the physician should determine whether <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> exists and whether the positive Coombs test may be a problem. For example, in addition to a positive direct Coombs test there is less often a positive indirect Coombs test which may interfere with cross matching of blood.</p>
<p>Before treatment is started, it is desirable to do a blood count (hematocrit, hemoglobin, or red cell count) for a baseline or to establish whether there is <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Periodic blood counts should be done during therapy to detect <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. It may be useful to do a direct Coombs test before therapy and at 6 and 12 months after the start of therapy.</p>
<p>If Coombs-positive <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> occurs, the cause may be methyldopa and the drug should be discontinued. Usually the <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> remits promptly. If not, corticosteroids may be given and other causes of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> should be considered. If the <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> is related to methyldopa, the drug should not be reinstituted.</p>
<p>When methyldopa causes Coombs positivity alone or with <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, the red cell is usually coated with gamma globulin of the IgG (gamma G) class only. The positive Coombs test may not revert to normal until weeks to months after methyldopa is stopped.</p>
<p>Should the need for transfusion arise in a patient receiving methyldopa, both a direct and indirect Coombs test should be performed. In the absence of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, usually only the direct Coombs test will be positive. A positive direct Coombs test alone will not interfere with typing or cross matching. If the indirect Coombs test is also positive, problems may arise in the major cross match and the assistance of a hematologist or transfusion expert will be needed.</p>
<p>Occasionally, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> has occurred within the first three weeks of methyldopa therapy, associated in some cases with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> or abnormalities in one or more liver function tests, such as serum alkaline phosphatase, serum transaminases (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT), bilirubin, and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span>, with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, may occur with onset usually within the first two to three months of therapy. In some patients the findings are consistent with those of <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>. In others the findings are consistent with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span>.</p>
<p>Rarely, fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> has been reported after use of methyldopa. These hepatic changes may represent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Periodic determination of hepatic function should be done particularly during the first 6 to 12 weeks of therapy or whenever an unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> occurs. If <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, abnormalities in liver function tests, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> appear, stop therapy with methyldopa. If caused by methyldopa, the temperature and abnormalities in liver function characteristically have reverted to normal when the drug was discontinued. Methyldopa should not be reinstituted in such patients.</p>
<p>Rarely, a reversible reduction of the white blood cell count with a primary effect on the granulocytes has been seen. The granulocyte count returned promptly to normal on discontinuance of the drug. Rare cases of <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> have been reported. In each instance, upon stopping the drug, the white cell count returned to normal. Reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> has occurred rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_502eaea6-a3a8-4336-9094-7cd04de7f82f"></a><a name="section-5.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Use with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p>Thiazides may add to or potentiate the action of other antihypertensive drugs.</p>
<p>Sensitivity reactions may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>The possibility of exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported.</p>
<p>Lithium generally should not be given with diuretics (see <a href="#i4i_interactions_id_di">PRECAUTIONS: Drug Interactions</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_general"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6458d79-464d-40db-a09e-593b87856071"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Methyldopa</span></h3>
<p class="First">Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</p>
<p>Some patients taking methyldopa experience clinical <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> which may be controlled by use of a diuretic. Methyldopa should not be continued if <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> progresses or signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> appear.</p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> has recurred occasionally after dialysis in patients given methyldopa because the drug is removed by this procedure.</p>
<p>Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease. Should these movements occur, stop therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_234e8cd7-15e1-4093-aaa1-ef1fc29f8362"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">All patients receiving diuretic therapy should be observed for evidence of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>; namely, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause, include dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially after prolonged therapy or when severe cirrhosis is present (see <a href="#i4i_contraindications_id_contraindications">CONTRAINDICATIONS</a> and <a href="#i4i_warnings_id_warnings">WARNINGS</a>). </p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>). <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may be avoided or treated by use of potassium sparing diuretics or potassium supplements such as foods with a high potassium content.</p>
<p>Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>), chloride replacement may be required in the treatment of <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.</p>
<p>Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazides.</p>
<p>In diabetic patients dosage adjustment of insulin or oral hypoglycemic agents may be required. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may occur with thiazide diuretics. Thus <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may become manifest during thiazide therapy.</p>
<p>The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident consider withholding or discontinuing diuretic therapy.</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
<p>Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be evidence of hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>. Thiazides should be discontinued before carrying out tests for parathyroid function.</p>
<p>Increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels may be associated with thiazide diuretic therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_11ffd97a-4e7f-4a8f-8c7d-51d1928da304"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7c07b355-eb9a-415a-8af2-6382cbc00509"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold">Methyldopa</span></h3>
<p class="First">Blood count, Coombs test and liver function tests, are recommended before initiating therapy and at periodic intervals (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cfff5e68-1d5b-4e7e-a57e-c8f4662b2757"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Periodic determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be done at appropriate intervals.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_di"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_adea0091-5c63-4150-9c74-c0c6b803f1f6"></a><a name="section-6.3.1"></a><p></p>
<h3><span class="Bold">Methyldopa</span></h3>
<p class="First">When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy.</p>
<p>Patients may require reduced doses of anesthetics when on methyldopa. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> does occur during anesthesia, it usually can be controlled by vasopressors. The adrenergic receptors remain sensitive during treatment with methyldopa.</p>
<p>Monoamine oxidase (MAO) inhibitors: See <a href="#i4i_contraindications_id_contraindications">CONTRAINDICATIONS</a>.</p>
<p>When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Read the prescribing information for lithium preparations.</p>
<p>Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. This may adversely affect blood pressure control in patients treated with methyldopa. Coadministration of methyldopa with ferrous sulfate or gluconate is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e501fe8a-a6bd-46fe-bc0a-b8fbd369ff40"></a><a name="section-6.3.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">When given concurrently the following drugs may interact with thiazide diuretics.</p>
<p><span class="Italics">Alcohol, barbiturates, or narcotics:</span> Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Antidiabetic drugs:</span> (Oral agents and insulin) dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics">Other antihypertensive drugs:</span> Additive effect or potentiation.</p>
<p><span class="Italics">Cholestyramine and colestipol resins: </span>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.</p>
<p><span class="Italics">Corticosteroids, ACTH:</span> Intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Pressor amines (e.g., norepinephrine): </span>Possible decreased response to pressor amines but not sufficient to preclude their use.</p>
<p><span class="Italics">Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine):</span> Possible increased responsiveness to the muscle relaxant.</p>
<p><span class="Italics">Lithium:</span> Generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations before use of such preparations with methyldopa and hydrochlorothiazide.</p>
<p><span class="Italics">Nonsteroidal Anti-inflammatory Drugs:</span> In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when methyldopa and hydrochlorothiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_f6876c03-b570-47a0-b07f-d942c9eca928"></a><a name="section-6.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e94beced-0678-4c3e-9417-a09752f2a8db"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Bold">Methyldopa</span></h3>
<p class="First">Methyldopa may interfere with measurement of: urinary uric acid by the phosphotungstate method, serum creatinine by the alkaline picrate method, and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> by colorimetric methods. Interference with spectrophotometric methods for <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> analysis has not been reported.</p>
<p>Since methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported. This will interfere with the diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. It is important to recognize this phenomenon before a patient with a possible <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> is subjected to surgery. Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, by those methods which convert VMA to vanillin. Methyldopa is not recommended for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. Rarely, when urine is exposed to air after voiding, it may darken because of breakdown of methyldopa or its metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdb1f257-5e5c-4d02-b6e2-4366cf3e56da"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Thiazides should be discontinued before carrying out tests for parathyroid function (see <a href="#i4i_precautions_general_id_general">PRECAUTIONS: General</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_658731c2-2d8e-480c-b0c6-4d643cee0eaa"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the effects upon fertility, mutagenic or carcinogenic potential of the combination.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b6d5c6e2-d55c-4304-a90d-3dd0dd054f01"></a><a name="section-6.5.1"></a><p></p>
<h3><span class="Bold">Methyldopa</span></h3>
<p class="First">No evidence of a tumorigenic effect was seen when methyldopa was given for two years to mice at doses up to 1800 mg/kg/day or to rats at doses up to 240 mg/kg/day (30 and 4 times the maximum recommended human dose in mice and rats, respectively, when compared on the basis of body weight; 2.5 and 0.6 times the maximum recommended human dose in mice and rats, respectively, when compared on the basis of body surface area; calculations assume a patient weight of 50 kg).</p>
<p>Methyldopa was not mutagenic in the Ames Test and did not increase chromosomal aberration or sister chromatid exchanges in Chinese hamster ovary cells. These <span class="Italics">in vitro </span>studies were carried out both with and without exogenous metabolic activation.</p>
<p>Fertility was unaffected when methyldopa was given to male and female rats at 100 mg/kg/day (1.7 times the maximum daily human dose when compared on the basis of body weight; 0.2 times the maximum daily human dose when compared on the basis of body surface area). Methyldopa decreased sperm count, sperm motility, the number of late spermatids and the male fertility index when given to male rats at 200 and 400 mg/kg/day (3.3 and 6.7 times the maximum daily human dose when compared on the basis of body weight; 0.5 and 1 times the maximum daily human dose when compared on the basis of body surface area).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_987c84c6-e6b3-45b5-ac8a-ae0bc8a87acd"></a><a name="section-6.5.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic <span class="Italics">in vitro </span>in the Ames mutagenicity assay of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>using <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or <span class="Italics">in vitro </span>in assays using mouse germinal cell chromosomes, Chinese Hamster bone marrow chromosomes, and the <span class="Italics">Drosophila </span>sex-linked recessive lethal trait gene. Positive test results were obtained only in the <span class="Italics">in vitro</span> CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 µg/mL, and in the <span class="Italics">Aspergillus nidulans</span> non-disjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5a46c9f7-1a8c-458c-a128-beb9ed3e0fe5"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Use of diuretics during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span> and there is no satisfactory evidence that they are useful in the treatment of toxemia.</p>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_c615500e-370b-4db6-b8e2-ebc7ff76ddaf"></a><a name="section-6.6.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_303a1880-e172-44a9-98a9-e6f130eeff14"></a><a name="section-6.6.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category C</span></h4>
<p class="First">Animal reproduction studies have not been conducted with methyldopa and hydrochlorothiazide. It is also not known whether methyldopa and hydrochlorothiazide can affect reproduction capacity or can cause fetal harm when given to a pregnant woman. Methyldopa and hydrochlorothiazide should be given to a pregnant woman only if clearly needed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d4e656e-903c-4d46-998e-f23494061d1c"></a><a name="section-6.6.1.1.1"></a><p></p>
<h5>Hydrochlorothiazide</h5>
<p class="First">Studies in which hydrochlorothiazide was orally administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3000 and 1000 mg hydrochlorothiazide/kg, respectively, provided no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9531c9b9-2472-4da2-a49c-ef470dc57104"></a><a name="section-6.6.1.1.2"></a><p></p>
<h5>Methyldopa</h5>
<p class="First">Reproduction studies performed with methyldopa at oral doses up to 1000 mg/kg in mice, 200 mg/kg in rabbits and 100 mg/kg in rats revealed no evidence of harm to the fetus. These doses are 16.6 times, 3.3 times and 1.7 times, respectively, the maximum daily human dose when compared on the basis of body weight; 1.4 times, 1.1 times and 0.2 times, respectively, when compared on the basis of body surface area; calculations assume a patient weight of 50 kg. There are however, no adequate and well-controlled studies in pregnant women in the first trimester of pregnancy. Because animal reproduction studies are not always predictive of human response, methyldopa should be used during pregnancy only if clearly needed.</p>
<p>Published reports of the use of methyldopa during all trimesters indicate that if this drug is used during pregnancy the possibility of fetal harm appears remote. In five studies, three of which were controlled, involving 332 pregnant hypertensive women, treatment with methyldopa was associated with an improved fetal outcome. The majority of these women were in the third trimester when methyldopa therapy was begun.</p>
<p>In one study, women who had begun methyldopa treatment between weeks 16 and 20 of pregnancy gave birth to infants whose average head circumference was reduced by a small amount (34.2 ± 1.7 cm vs. 34.6 ± 1.3 cm [mean ± 1 S.D.]). Long-term follow-up of 195 (97.5%) of the children born to methyldopa-treated pregnant women (including those who began treatment between weeks 16 and 20) failed to uncover any significant adverse effect on the children. At four years of age, the <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span> commonly seen in children born to hypertensive mothers was less evident in those whose mothers were treated with methyldopa during pregnancy than those whose mothers were untreated. The children of the treated group scored consistently higher than the children of the untreated group on five major indices of intellectual and motor development. At age 7 and one-half developmental scores and intelligence indices showed no significant differences in children of treated or untreated hypertensive women.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_a4ce37b6-0ca9-4185-81c3-2cf615c93d2d"></a><a name="section-6.6.2"></a><p></p>
<h3><span class="Bold">Nonteratogenic Effects</span></h3>
<p class="First">Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions which have occurred in adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_c6463587-186b-4384-8216-596ebf802cb8"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Methyldopa and thiazides appear in breast milk. Therefore, because of the potential for serious adverse reactions in nursing infants from hydrochlorothiazide, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_6260b020-3fe4-4bc9-9c9f-f1fd5a9a8709"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of methyldopa and hydrochlorothiazide in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_beae09ca-7b13-4b78-9fa9-cd46c555379b"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of methyldopa and hydrochlorothiazide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ef86c100-daa7-48fc-888c-2e040a5bfa5b"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07f513ad-c4af-4c85-b11c-accc2db46bd3"></a><a name="section-7.1"></a><p></p>
<h2>Methyldopa</h2>
<p class="First">Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> may be noted as early and transient symptoms. However, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular: </span></span> Aggravation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, prolonged carotid sinus <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (decrease daily dosage), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p><span class="Bold"><span class="Italics">Digestive:</span></span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, sore or "black" tongue, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4091513" conceptname="Passing flatus">flatus</span>, dryness of mouth.</p>
<p><span class="Bold"><span class="Italics">Endocrine: </span></span>  <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>.</p>
<p><span class="Bold"><span class="Italics">Hematologic: </span></span> <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>; positive tests for <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span>, LE cells, and rheumatoid factor, positive Coombs test.</p>
<p><span class="Bold"><span class="Italics">Hepatic:</span></span> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Liver disorders</span> including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span></span> <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, lupus-like syndrome, drug-related <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Bold"><span class="Italics">Nervous System/Psychiatric: </span></span> <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>, Bell's <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">palsy</span>, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> and reversible mild psychoses or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, sedation, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>.</p>
<p><span class="Bold"><span class="Italics">Metabolic:</span></span> Rise in BUN.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal:</span></span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, with or without <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Bold"><span class="Italics">Respiratory:</span></span> <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal stuffiness</span>.</p>
<p><span class="Bold"><span class="Italics">Skin: </span></span> <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Bold"><span class="Italics">Urogenital: </span></span> <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, lactation, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2da93e4f-340c-4a5c-99fa-9ba632a3ebaa"></a><a name="section-7.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First"><span class="Bold"><span class="Italics">Body as a Whole: </span></span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs).</p>
<p><span class="Bold"><span class="Italics">Digestive: </span></span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span></span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Bold"><span class="Italics">Metabolic: </span></span> <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span> (see <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a>), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>.</p>
<p><span class="Italics"><span class="Bold">Musculoskeletal</span>: </span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span>.</p>
<p><span class="Bold"><span class="Italics">Nervous System/Psychiatric: </span></span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</p>
<p><span class="Bold"><span class="Italics">Renal:</span></span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>. (See <a href="#i4i_warnings_id_warnings">WARNINGS</a>.)</p>
<p><span class="Bold"><span class="Italics">Skin: </span></span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
<p><span class="Bold"><span class="Italics">Special Senses: </span></span> Transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.</p>
<p><span class="Bold"><span class="Italics">Urogenital: </span></span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_2a94aa6c-3ce0-48ef-9525-4e48a77bbb19"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute overdosage may produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4091513" conceptname="Passing flatus">flatus</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>).</p>
<p>In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion. Otherwise, management includes special attention to cardiac rate and output, blood volume, electrolyte balance, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, urinary function and cerebral activity.</p>
<p>Sympathomimetic drugs (e.g., norepinephrine, epinephrine, metaraminol bitartrate) may be indicated. Methyldopa is dialyzable. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.</p>
<p>The oral LD<span class="Sub">50</span> of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d780c0ab-cdee-4b7d-be7d-eaf24206b13c"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DOSAGE MUST BE INDIVIDUALIZED, AS DETERMINED BY TITRATION OF THE INDIVIDUAL COMPONENTS (see <a href="#b_warning">boxed WARNING</a>). Once the patient has been successfully titrated, methyldopa and hydrochlorothiazide tablets may be substituted if the previously determined titrated doses are the same as in the combination. The usual starting dosage is one 250 mg/15 mg tablet of methyldopa and hydrochlorothiazide two or three times a day or one 250 mg/25 mg tablet of methyldopa and hydrochlorothiazide two times a day. Alternatively, one 500 mg/30 mg tablet of methyldopa and hydrochlorothiazide or a 500 mg/50 mg tablet of methyldopa and hydrochlorothiazide once daily may be used. Hydrochlorothiazide doses greater than 50 mg daily should be avoided.</p>
<p>Hydrochlorothiazide can be given at doses of 12.5 mg to 50 mg per day when used alone. The usual daily dosage of methyldopa is 500 mg to 2 g. To minimize the sedation associated with methyldopa, start dosage increases in the evening. The maximum recommended daily dose of methyldopa is 3 g.</p>
<p>Occasionally tolerance to methyldopa may occur, usually between the second and third month of therapy. Additional separate doses of methyldopa or replacement of methyldopa and hydrochlorothiazide tablets with single entity agents is necessary until the new effective dose ratio is reestablished by titration.</p>
<p>If methyldopa and hydrochlorothiazide does not adequately control blood pressure, additional doses of other agents may be given. When methyldopa and hydrochlorothiazide is given with antihypertensives other than thiazides, the initial dosage of methyldopa should be limited to 500 mg daily in divided doses and the dose of these other agents may need to be adjusted to effect a smooth transition.</p>
<p>Since both components, methyldopa and hydrochlorothiazide, have a relatively short duration of action, withdrawal is followed by return of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> usually within 48 hours. This is not complicated by an overshoot of blood pressure.</p>
<p>Since methyldopa is largely excreted by the kidney, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> may respond to smaller doses. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_502b2f08-b25d-4f0b-a97b-6ef501e1e834"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Methyldopa and Hydrochlorothiazide Tablets, USP are available as follows:</p>
<p>The 250 mg/15 mg tablets are green, round, unscored, film-coated tablets debossed with <span class="Bold">MYLAN</span> on one side and <span class="Bold">507 </span>on the other side. They are available as follows:</p>
<p>NDC 0378-0507-01<br>bottles of 100 tablets</p>
<p>The 250 mg/25 mg tablets are green, capsule-shaped, unscored, film-coated tablets debossed with <span class="Bold">MYLAN</span> on one side and <span class="Bold">711</span> on the other side. They are available as follows:</p>
<p>NDC 0378-0711-01<br>bottles of 100 tablets</p>
<p>NDC 0378-0711-10<br>bottles of 1000 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p>Mylan Pharmaceuticals Inc.</p>
<p>Morgantown, WV 26505</p>
<p>REVISED NOVEMBER 2005</p>
<p>MDHZ:R5AQ </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_271a0457-4a5b-40ab-8c76-1df84b0ff724"></a><a name="section-11"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 250 mg/15 mg</span></p>
<p><span class="Bold">NDC 0378-0507-01</span></p>
<p><span class="Bold">Methyldopa and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">250 mg/15 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each film-coated tablet contains:<br>Methyldopa, USP (calculated as <br>anhydrous)                250 mg<br>Hydrochlorothiazide, USP      15 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0507A10</span></p>
<div class="Figure">
<a name="id1070"></a><img alt="Methyldopa and Hydrochlorothiazide Tablets, USP 250 mg/15 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5bf74178-66b8-44d4-a87d-1fd760b94ad3&amp;name=20299cba-fa9a-40ff-9737-06e052920321-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ab51410e-1599-4b35-a672-3e4a73ed5d6f"></a><a name="section-12"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 250 mg/25 mg</span></p>
<p><span class="Bold">NDC 0378-0711-01</span></p>
<p><span class="Bold">Methyldopa and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">250 mg/25 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each film-coated tablet contains:<br>Methyldopa, USP (calculated as <br>anhydrous)                250 mg<br>Hydrochlorothiazide, USP      25 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0711A13</span></p>
<div class="Figure">
<a name="id1122"></a><img alt="Methyldopa and Hydrochlorothiazide Tablets, USP 250 mg/25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5bf74178-66b8-44d4-a87d-1fd760b94ad3&amp;name=20299cba-fa9a-40ff-9737-06e052920321-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHYLDOPA AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">methyldopa and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0507</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLDOPA</strong> (METHYLDOPA ANHYDROUS) </td>
<td class="formItem">METHYLDOPA ANHYDROUS</td>
<td class="formItem">250 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;507</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0507-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070265</td>
<td class="formItem">01/23/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHYLDOPA AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">methyldopa and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0711</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLDOPA</strong> (METHYLDOPA ANHYDROUS) </td>
<td class="formItem">METHYLDOPA ANHYDROUS</td>
<td class="formItem">250 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;711</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0711-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070265</td>
<td class="formItem">01/23/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>939cd970-6d0d-4403-a7fa-21a2b87555df</div>
<div>Set id: 5bf74178-66b8-44d4-a87d-1fd760b94ad3</div>
<div>Version: 6</div>
<div>Effective Time: 20100118</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
